Prevalence, Severity, and Unmet Need for Treatment of Mental Disorders in the World Health Organization World Mental Health Surveys
Abstract
To estimate prevalence, severity, and treatment of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) mental disorders in 14 countries (6 less developed, 8 developed) in the World Health Organization (WHO) World Mental Health (WMH) Survey Initiative. DESIGN, SETTING, AND PARTICIPANTS: Face-to-face household surveys of 60 463 community adults conducted from 2001-2003 in 14 countries in the Americas, Europe, the Middle East, Africa, and Asia. MAIN OUTCOME MEASURES: The DSM-IV disorders, severity, and treatment were assessed with the WMH version of the WHO Composite International Diagnostic Interview (WMH-CIDI), a fully structured, lay-administered psychiatric diagnostic interview.
The prevalence of having any WMH-CIDI/DSM-IV disorder in the prior year varied widely, from 4.3% in Shanghai to 26.4% in the United States, with an interquartile range (IQR) of 9.1%-16.9%. Between 33.1% (Colombia) and 80.9% (Nigeria) of 12-month cases were mild (IQR, 40.2%-53.3%). Serious disorders were associated with substantial role disability. Although disorder severity was correlated with probability of treatment in almost all countries, 35.5% to 50.3% of serious cases in developed countries and 76.3% to 85.4% in less-developed countries received no treatment in the 12 months before the interview. Due to the high prevalence of mild and subthreshold cases, the number of those who received treatment far exceeds the number of untreated serious cases in every country.
Citation impact
- FWCI
- 154.55
- Percentile
- 100%
- References
- 61
Authors
1- TWThe WHO World Mental Health Survey ConsortiumCorresponding
Topics & keywords
- Medicine
- Mental health
- CIDI
- Interquartile range
- Psychiatry
- Developing country
- Prevalence of mental disorders
- Internal medicine
- Partnerships for the goals
Funding
- RWRobert Wood Johnson FoundationAwards: 044708, Grant 044708
- JDJohn D. and Catherine T. MacArthur FoundationAward: R01 DA016558
- JWJohn W. Alden Trust
- ELEli Lilly and Company
- PPfizer
- GGlaxoSmithKline
- WHWorld Health Organization
- MSMichigan State University
- ECEuropean CommissionAward: QLG5-1999-01042
- GDGeneralitat de CatalunyaAward: 01042
- CUChinese University of Hong Kong
- RPRegione PiemonteAward: 00/0028
- SASubstance Abuse and Mental Health Services Administration
- COCollege of Engineering, Michigan State University
- PFPfizer FoundationAward: R01 DA016558
- PAPan American Health Organization
- IDInstituto de Salud Carlos IIIAward: FIS 00/0028
- NINational Institute of Mental HealthAwards: U01-MH60220, MH60220
- NINational Institute on Drug AbuseAward: R01 DA016558